PulseFlow Technologies Completes Nearly RMB 100 Million Series B Financing, Leading Intelligent Diagnosis and Treatment of Cardio-Cerebrovascular Diseases in China

Recently, VCBeat (WeChat ID: vcbeat) learned that ArteryFlow Technology, a leader in intelligent diagnosis and treatment of cardiovascular and cerebrovascular diseases, has completed a Series B financing round of nearly RMB 100 million. Dr. Xiang Jianping, Founder and CEO of ArteryFlow Technology, stated that the funds from this round will be used to further promote and implement the commercialization of the company’s functional assessment products for cardiovascular and cerebrovascular diseases, expand its sales and R&D teams, and carry out new product development and regulatory registration filings.

As an innovative technology company that leverages medical big data, computational simulation technologies, and artificial intelligence algorithms to provide precise and personalized diagnosis and treatment for cardiovascular and cerebrovascular diseases, ArteryFlow Technology achieved remarkable success in 2021. This was a breakout year for the company’s product certifications. To date, ArteryFlow Technology has obtained registration certificates from China’s NMPA, the U.S. FDA, and the European CE for 11 products. Among these, seven products have received NMPA registration in China, three have obtained European CE certification, and one has secured U.S. FDA clearance.

On April 26, 2021, ArteryFlow Technology’s AneuFlow, a functional assessment product for cerebrovascular and cardiovascular diseases^®、AccuCT^®、AccuAngio^®Approved for Launch in China: Three Certificates Issued Simultaneously!

ArteryFlow Technology's Self-Developed Auxiliary Diagnostic System for Intracranial AneurysmsAneuFlow^®The First Hemodynamics-Based Intracranial Aneurysm Assessment System in China. Meanwhile, ArteryFlow Technology’s non-invasive coronary functional assessment product—AccuCT Based on Coronary CTA^®and AccuAngio based on coronary angiography^®"Simultaneously obtaining the market registration certificate, ArteryFlow Technology becomes the first company in China to possess coronary functional assessment products based on both coronary CT and angiography.". This marks another milestone for the company following the simultaneous CE certification of these two products by the European Union.

Subsequently, on May 28, 2021, ArteryFlow Technology held a launch event for its cardiovascular and cerebrovascular functional assessment platform during the 15th Oriental Congress of Cardiology (OCC 2021), under the theme “Intelligent Heart and Brain, Function First.”

At the conference, ArteryFlow Technology made a significant launch of three approved innovative products for functional assessment of cardiovascular and cerebrovascular diseases—AneuFlow^®、AccuCT^®and AccuAngio^®Academician Ge Junbo, Professor Wang Jian’an, and Professor Shen Li from the cardiovascular field, along with cerebrovascular disease experts Professor Liu Jianmin and Professor Jiang Weijian, attended the launch event to jointly witness the market debut of ArteryFlow Technology’s products.

In the same year, on September 10, 2021,ArteryFlow Technology’s Independently Developed Coronary Angiography-Based Functional Assessment and Analysis Software: AccuFFR^®Angio has obtained U.S. FDA 510(k) clearance。

AccuFFR^®Angio has pioneered a wire-free era for fractional flow reserve (FFR) assessment, enabling non-invasive evaluation of FFR values in stenotic coronary arteries. This allows for quantitative analysis of the severity of myocardial ischemia in patients, thereby guiding percutaneous coronary intervention, with an accuracy exceeding 93%.

Previously, ArteryFlow Technology’s independently developed AccuFFR^®The product series has obtained EU CE certification, making the company the first globally in the CE market to offer functional assessment products based on both coronary CT and coronary angiography, with independent software and hardware offerings. Following this AccuFFR^®Following the U.S. approval of Angio products,ArteryFlow Technology Becomes the First Company to Obtain Regulatory Approval for Its Angiography-Based Coronary Physiology Product in China, Europe, and the United States。

Also on September 10, 2021, ArteryFlow Technology’s intracranial surgical planning product, AneuGuide™, entered the National Medical Products Administration’s Special Examination and Approval Procedure for Innovative Medical Devices. Eighteen days later, AneuGuide™ successfully obtained its product registration certificate, setting a “new speed” record for the approval of intelligent diagnostic and therapeutic products.

AneuGuide™Patient-specific 3D models of intracranial vessels can be created using three-dimensional medical images of the patient’s brain, providing rapid and precise solutions for flow diverter stent sizing and optimization of implantation positioning.AneuGuide™It provides visualization of multiple critical parameters, allowing users to virtually drag and position the stent to dynamically display real-time changes in metal coverage, wall apposition, porosity, and other metrics, thereby facilitating optimal flow diverter selection and surgical planning for patients.

While ArteryFlow Technology’s various products obtained registration certificates to gain market access, the company was also accelerating the commercialization of its products. ArteryFlow Technology began building its marketing team in early 2021 and actively expanded its market presence.The company’s marketing team currently comprises over 40 professionals, specializing in intelligent diagnosis and treatment solutions for cardiovascular and cerebrovascular diseases. Its coverage extends across more than 30 provinces, autonomous regions, and municipalities directly under the central government in China, as well as two major overseas markets in Europe and the United States. The company’s products have been implemented in nearly 200 general hospitals and specialized cardiovascular and cerebrovascular hospitals.

In the cardiovascular product sector, the company has established a comprehensive strategic cooperation model—encompassing academic promotion, product R&D, and commercial implementation—with leading hospitals including Zhongshan Hospital Fudan University (Shanghai), The Second Affiliated Hospital of Zhejiang University School of Medicine, Beijing Anzhen Hospital, and PLA General Hospital (Beijing 301 Hospital). Furthermore, leveraging its industry-leading cerebrovascular products, ArteryFlow Technology is actively promoting new concepts and methods for non-invasive diagnosis and treatment. By partnering with national cerebrovascular diagnosis and treatment centers such as Shanghai Changhai Hospital, Beijing Tiantan Hospital, and Huashan Hospital Fudan University (Shanghai), the company achieves end-to-end R&D and promotion of products for stroke management.

Meanwhile, the company is also launching and implementing new business models. By collaborating with internet hospitals to establish a complete commercial closed loop connecting patients, physical hospitals, internet hospitals, and product/service providers, it has innovatively achieved the commercial deployment of its products within the bounds of laws and regulations. Currently, this model has facilitated the commercial implementation of the company’s products in more than 50 hospitals, with over 1,000 paid cases recorded.

With the widespread adoption and deepening integration of intelligent diagnosis and treatment concepts, coupled with the substantial market size in cardiovascular and cerebrovascular care, and the synergy between traditional models and emerging business models, the company’s commercial sales in the field of intelligent cardiovascular and cerebrovascular diagnosis and treatment are poised for explosive growth in the coming years.

2021 was not only a “bumper year” for ArteryFlow Technology in terms of product approvals and commercialization, but also the inaugural year for its marketing and academic promotion.

October 10, ArteryFlow TechnologyCombinedCCI Innovation AcademyEstablished“China Cardiovascular Physicians Innovation Club Hemodynamics Joint Laboratory” Officially Unveiled. The laboratory aims to strengthen hemodynamic research in the pan-vascular field. In the future, it will launch a series of joint experiments in basic research and innovation, including hemodynamic monitoring, guidance, and evaluation of endovascular treatment strategies. By leveraging the extensive applications of hemodynamics in the pan-vascular domain, the laboratory seeks to promote sustained medical-engineering collaboration and innovative translation.

To establish brand advantages, ArteryFlow Technology has created its own professional academic education brand, “ArteryFlow Academy,” which comprises two components: the offline program “Zhiliu Dizhu” and the online platform “ArteryFlow Online.” The goal of ArteryFlow Academy is to promote intelligent diagnostic and therapeutic technologies for cardiovascular and cerebrovascular diseases. By organizing regular exchanges among physicians to share the latest advancements, case studies, and practical insights in the field of intelligent diagnosis and treatment of cardiovascular and cerebrovascular diseases, it aims to build ArteryFlow’s own “academic community” and “fan base.” This year, ArteryFlow Academy has organized nearly 20 events, significantly enhancing customer stickiness.

Furthermore, ArteryFlow Technology actively participates in various top-tier academic conferences both domestically and internationally, leveraging its extensive network of experts to promote the company and introduce corresponding disease management solutions. This year, ArteryFlow Technology hosted more than 20 national academic symposia focused on intelligent diagnosis and treatment of cardiovascular and cerebrovascular diseases, and participated in over 40 regional academic conferences, earning widespread recognition and favor from experts across various fields.

As a pioneer in intelligent diagnosis and treatment of cardiovascular and cerebrovascular diseases, ArteryFlow Technology is headquartered in Hangzhou. It is a national high-tech enterprise that leverages medical big data, computational simulation technology, and artificial intelligence algorithms to provide precise and personalized diagnosis and treatment for cardiovascular and cerebrovascular conditions. Its core R&D team consists of PhDs and master’s graduates from world-class universities such as MIT and Imperial College London. The team possesses extensive technical expertise in computational simulation, artificial intelligence, and medical imaging, has published hundreds of academic papers, and combines strong technical capabilities with profound clinical insights.

The company provides comprehensive solutions for cardiovascular and cerebrovascular diseases, with products covering intelligent screening, testing, diagnosis, and surgical planning for these conditions. Its core offerings include AccuFFR, a full imaging chain product for coronary functional assessment.^®ct、AccuFFR^®angio、AccuFFR^®IVUS and AccuFFR^®OCT; DeepLV, a Product for Cardiac Functional Assessment^®as well as the valve surgery planning product AccuValve™; and the cerebral hemorrhage stroke product AneuFlow^®、AneuPlan^®, AneuGuide™ and the full ischemic imaging chain product AccuICH^®、AccuASPECTS^®、AccuLVO^®、AccuCTP^®and AccuICAS^®etc. Relying on the ArteryFlow Cloud Platform, ArteryFlow Technology provides precise and personalized diagnosis and treatment services for cardiovascular and cerebrovascular diseases to hospitals, imaging centers, health checkup institutions, and patients, thereby delivering an improved diagnostic and therapeutic experience for both patients and clinicians.

ArteryFlow Technology’s innovative products have gained global industry recognition. At the Innovation in Cardiovascular Interventions (ICI) conference held in Tel Aviv, Israel, from December 8 to 10, 2019, AccuFFR—a series of innovative, non-invasive functional assessment products for coronary arteries with independent intellectual property rights, developed by ArteryFlow Technology—stood out among numerous Chinese-Israeli projects and won the 2019 Best Innovation Award in the cardiovascular field. Furthermore, in December 2020, at the 4th World Life Science Conference, witnessed by 26 academicians, ArteryFlow Technology secured first place for the Life Science Technology Innovation Award.

The ArteryFlow team has engaged in deep collaboration with clinicians from over a hundred hospitals both domestically and internationally. It has jointly established the Hemodynamics Joint Laboratory and the AI Research Center for Cardiovascular and Cerebrovascular Diseases with CCI, and has successfully secured dozens of research grants through joint applications. The company maintains close partnerships with the world-leading interventional center, GVI in Buffalo, USA, as well as with top-tier Chinese hospitals specializing in cardiovascular and cerebrovascular diseases, including Zhongshan Hospital, Changhai Hospital, Huashan Hospital, Tiantan Hospital, the Second Affiliated Hospital of Zhejiang University School of Medicine, and Zhejiang Provincial People’s Hospital, yielding numerous significant achievements.